modelB05CX03
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Glycine | |
| ATC code: | B05CX03 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 24000 | mg |
| volume of distribution: | 0.4 | L |
| clearance: | 100 | ml/min |
| other parameters in model implementation | ||
Glycine is a simple amino acid that serves as an inhibitory neurotransmitter in the central nervous system. It is also used medically as a sterile, non-electrolyte irrigating solution during transurethral surgical procedures, particularly in urology. There is no current evidence supporting its use as an approved systemic drug for other therapeutic indications.
Pharmacokinetics
No direct pharmacokinetic studies for intravenous glycine irrigation solution in healthy adults or patients could be identified in published literature. Systemic glycine is rapidly and extensively distributed, metabolized primarily in the liver, and excreted renally. Values below are estimated based on related amino acid data and clinical context.
References
Upert, G, et al., & Ermert, P (2021). Emerging peptide antibiotics with therapeutic potential. Medicine in drug discovery 9 100078–None. DOI:10.1016/j.medidd.2020.100078 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33398258
Neumeister, A, et al., & Frost, JJ (2006). Cerebral metabolic effects of intravenous glycine in healthy human subjects. Journal of clinical psychopharmacology 26(6) 595–599. DOI:10.1097/01.jcp.0000245558.14284.aa PUBMED:https://pubmed.ncbi.nlm.nih.gov/17110816
Bi, YA, et al., & Varma, MVS (2024). Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay. Clinical pharmacology and therapeutics 115(6) 1336–1345. DOI:10.1002/cpt.3215 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38404228
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)